FRACS

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Clinical Trials, Medical Supplies, Sale, Aortoiliac occlusive disease, DCB, Cell, Sundance, ISET, Master of Medicine, Freedom, Restenosis, Safety, PHD, Ambient occlusion, PP, MS, Pharmaceutical industry, MBBS, Anesthetic, FRACS

The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.

Key Points: 
  • The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.
  • Professor Varcoe previously presented SWING Trial 12-month data on January 18th at the 35th Annual International Symposium on Endovascular Therapy (ISET) conference.
  • Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings

Retrieved on: 
Wednesday, April 26, 2023
Health, Other Health, General Health, Clinical Trials, Research, Science, Biotechnology, No-scalpel vasectomy, Abstract, Male, Reproductive medicine, MBBS, ADAM, AUA, Birth, Clinical trial, Vasectomy, American Urological Association, Doctor of Philosophy, Royal Melbourne Hospital, Epworth HealthCare, MD, Patient, Azoospermia, European Association of Urology, Safety, EAU, Birth control, Pharmaceutical industry, FRACS, Urology

The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).

Key Points: 
  • The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).
  • The podium presentations by Nathan Lawrentschuk at AUA and Paul Anderson at EAU highlight the early research findings on the ADAM System.
  • Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception.
  • The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

Retrieved on: 
Thursday, January 19, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MS, CDR, SCB-125, ISET, PHD, Death, Sirolimus, Patient, Master of Medicine, International Symposium on Endovascular Therapy, PAD, SCB, Sundance, Pharmaceutical industry, FRACS, MBBS

The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.

Key Points: 
  • The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.
  • At ISET, SWING co-lead investigator Professor Ramon Varcoe, MBBS, MS, FRACS, PHD, MMed (ClinEpi), reinforced key findings from the SWING trial.
  • Rather than using encapsulation, the Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface, a method the Company describes as Crystalline Drug Release, or CDR.
  • When inflated, the Sundance™ SCB transfers this crystalline drug form to the vessel wall, whereupon the crystalized drug itself serves as the drug depot in a process that eliminates the need for a polymer depot.

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

Retrieved on: 
Monday, January 16, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, FRANZCR, Cell, MS, Auckland City Hospital, Aortoiliac occlusive disease, Safety, SCB Park Plaza, ISET, PHD, ONZM, Master of Medicine, Sale, DCB, Restenosis, International Symposium on Endovascular Therapy, Pharmaceutical industry, FRACS, Bachelor of Medicine, Bachelor of Surgery, MBBS, Anesthetic

The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.

Key Points: 
  • The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.
  • Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug release platform for sirolimus-coated balloons (SCBs) in connection with 12-month data from the SWING trial.
  • Professor Varcoe recently presented SWING Trial 12-month data on Nov. 16 at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium).
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

Retrieved on: 
Thursday, November 17, 2022
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, MALE, Restenosis, Sale, Ambient occlusion, Peripheral artery disease, Cell, DCB, Freedom, PHD, PP, FRANZCR, MS, Safety, HIV disease progression rates, IVD, Disease, Master of Medicine, Annual report, ONZM, Growth, Classification, MD, Aortoiliac occlusive disease, Pharmaceutical industry, Medical imaging, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery

The primary efficacy endpoint is the rate of late lumen loss at 6 months, as assessed by quantitative vascular angiography.

Key Points: 
  • The primary efficacy endpoint is the rate of late lumen loss at 6 months, as assessed by quantitative vascular angiography.
  • Both primary endpoints of the SWING Trial were achieved.
  • Primary safety endpoint data showed no perioperative deaths or major amputations at 30 days, and just one major re-intervention was reported among the 35 trial subjects.
  • The SWING Trial demonstrates that the Sundance Sirolimus DCB has tremendous promise and warrants evaluation in a large-scale pivotal trial.

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Retrieved on: 
Friday, November 11, 2022
Medical Devices, Health, Surgery, Clinical Trials, General Health, Pharmaceutical, Aortoiliac occlusive disease, Sale, Company, Annual report, NASDAQ, Disease, Auckland City Hospital, Technology, Cell, DCB, SEC, Safety, Investor, 3rd Floor, Forward-looking statement, MS, Restenosis, Master of Medicine, FRANZCR, AMP, Growth, Amputation, PHD, ONZM, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, FRACS, Anesthetic, MBBS

The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Key Points: 
  • The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
  • Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, Director of Northern Region Interventional Radiology Service at Auckland City Hospital in Auckland, New Zealand, is also a co-lead investigator for the SWING Trial.
  • Professor Varcoe recently presented SWING Trial 6-month data on October 11 as part of the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays.

6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Retrieved on: 
Tuesday, October 11, 2022
Health, Medical Devices, Surgery, General Health, Clinical Trials, Pharmaceutical, Cardiology, Disease, Sale, SEC, LLL, MS, Population, CLI, Growth, Investor, FIH, PHD, Annual report, NASDAQ, DCB, Cell, Amputation, Restenosis, Technology, ONZM, Company, IVD, MD, RVD, Safety, Diabetes, AMP, FRANZCR, Master of Medicine, Forward-looking statement, Aortoiliac occlusive disease, Medical device, Pharmaceutical industry, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery

The studys primary safety endpoint data showed no perioperative deaths or major amputations at 30 days and just one major re-intervention was reported among the 35 trial subjects.

Key Points: 
  • The studys primary safety endpoint data showed no perioperative deaths or major amputations at 30 days and just one major re-intervention was reported among the 35 trial subjects.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.
  • Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.
  • The content of Surmodics website is not part of this press release or part of any filings that the company makes with the SEC.

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

Retrieved on: 
Friday, October 7, 2022
Biotechnology, Pharmaceutical, Surgery, General Health, Health, Medical Devices, Clinical Trials, Other Health, Quality of life, Disease, Risk, SEC, Sale, MS, Growth, Investor, PHD, Annual report, NASDAQ, Patient, Cell, Amputation, Restenosis, Technology, ONZM, Company, Auckland City Hospital, Safety, AMP, FRANZCR, Master of Medicine, Forward-looking statement, Aortoiliac occlusive disease, Pharmaceutical industry, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery, Anesthetic

The session will be held on Tuesday, October 11, at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.

Key Points: 
  • The session will be held on Tuesday, October 11, at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • He will review safety and efficacy data collected through 6-months of follow-up for 35 patients with occlusive disease of the infra-popliteal arteries who were treated at study sites in Australia, New Zealand, or locations in Europe.
  • Study subjects will be followed for 36 months after the index procedure.
  • I am excited to present the 6-month SWING data to an audience of my peers at AMP Europe.

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Retrieved on: 
Monday, August 1, 2022
Research, Medical Devices, Surgery, Publishing, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Sentinel, Literature, Melanoma, Review, NYSE American, University, FRCSE, MBBS, SLN, Manuscript, United Kingdom, Otorhinolaryngology, Lymph, Research, Securities Exchange Act of 1934, CM, Decision-making, Macrophage, Coronavirus, Surgical oncology, SEC, Securities Act of 1933, PMID, Disease, Neck, Annual report, Lists of World Heritage Sites, Risk, Health, Forward-looking statement, NYSE, History, Biopharmaceutical, Principal, Technetium-99m, Oral cancer, B cell, Patient, Department, Faculty, Pharmaceutical industry, FRACS, Sentinel lymph node, Medicine, Lymph node, EU, Technetium (99mTc) tilmanocept

Despite this widespread acceptance, several different radiocolloids and dyes have been used, resulting in a non-standardized method of localizing and retrieving sentinel lymph nodes.

Key Points: 
  • Despite this widespread acceptance, several different radiocolloids and dyes have been used, resulting in a non-standardized method of localizing and retrieving sentinel lymph nodes.
  • The use of Tc99m tilmanocept as a radiopharmaceutical for SLNB in CM and OCSCC has not been studied in Australia to date.
  • This prospective study had as its aim the investigation of Tc99m tilmanocept use to evaluate its application, suitability, and reliability in an Australian setting.
  • Tc99m tilmanocept also demonstrated high tissue specificity (100%), with lymph nodal tissue confirmed histologically, with no false positives.

Exactech to Showcase New Technology and Product Innovations at AAOS 2022 Annual Meeting, Booth #3014

Retrieved on: 
Monday, March 21, 2022
Surgery, Health, Medical Devices, LinkedIn, DNB, Active, Multimedia, Percussion section, Doctor of Philosophy, American Academy of Orthopaedic Surgeons, Motion, CT, Hospital, AAOS, William H. Harris (orthopaedic surgeon), View, ISTA, Computer, Technology, Annual general meeting, Twitter, Tibia, Surgeon, Knee, MS, Accuracy and precision, American Academy, Physician, YouTube, LD, Instagram, Patient, Medical device, MD, Pacific Ocean, FRACS

Surgeon attendees will be able to experience all the innovations through product demonstrations and an immersive experience in the technology suite.

Key Points: 
  • Surgeon attendees will be able to experience all the innovations through product demonstrations and an immersive experience in the technology suite.
  • View the full release here: https://www.businesswire.com/news/home/20220321005661/en/
    Exactech to Showcase New Technology and Product Innovations at AAOS 2022 Annual Meeting, Booth #3014 (Photo: Business Wire)
    We are pleased to showcase an exciting array of transformative products and technologies this year, said Exactech President and CEO Darin Johnson.
  • Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific.
  • Spartan Hip Stem and Logical Cup are manufactured by Signature Orthopaedics and distributed by Exactech, Inc.